Sample collection
Diagnostic TestSamples of blood, urine and saliva will be collected at up to five successive time points.
NCT Number: NCT03306563
The objective of the study is to confirm the clinical relevance of the novel biomarker for traumatic brain injury (TBI) detection. Samples of blood, urine and saliva will be collected from a) patients with suspected TBI (isolated), b) patients with orthopedic injury, and c) healthy controls. The sponsor will do biochemical investigations for the samples to evaluate the presence, level and structure of the targeted biomarker.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Satakunta Central Hospital, Pori, Finland
The study will analyze and compare the levels of certain biomolecules and cellular degradation products which are released upon a brain injury and which become detectable in the body fluids. Patients with a traumatic brain injury are supposed to express these biomarkers in their body fluids while orthopedic trauma patients and healthy controls are supposed to be undetectable with respect to these biomolecules. The study is a case-control study where the study subjects with a property (injured) are compared to subjects without the property (healthy). The brain injury patient group will consist of subjects who entered the Emergency Department of the hospital with a suspected TBI. The orthopedic patient group will consists of patients who were admitted with a bone fracture in the limbs, but without a suspected TBI. The control group will consist of healthy subjects who will be recruited to the study by the activities of the study personnel.
The entire study is split into two successive parts. In the first Part I, 18 - 24 subjects will be recruited in each group. In the second part, the number of the patients with suspected TBI will be added to up to 100 in order to receive an adequate number of samples and to gain sufficient statistical significance between the brain injury severities and in successive sampling time points.
The collected samples and relevant clinical data of each subject will be supplied to the sponsor who will perform to the samples 1) Biochemical analysis for the presence and level of the biomarker, and 2) Biomarker profiling and structure analysis by LC/MS.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Samples of blood, urine and saliva will be collected at up to five successive time points.
Time frame: One year (1 year)
Analytical measurement of the biomarker level. (biodegradation glycans detected by HPLC-MS).
Medicortex Finland Oy
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01618786
Accidental Falls, Bone Fracture
Burnaby, British Columbia, Canada
View Trial DetailsNCT04485494
Athletic Injuries, Brain Concussion
Limerick, Munster, Ireland
View Trial DetailsNCT06595914
Brain Concussion, Brain Diseases
Milwaukee, Wisconsin, United States
View Trial DetailsNCT06105892
Brain Concussion, Brain Diseases
Albuquerque, New Mexico, United States
View Trial Details